ABOUT STAMPEDE

Prostate cancer accounts for around one fifth of all male cancers. In the UK there are ~47,000 new cases each year and ~11,000 deaths.

STAMPEDE aims to provide evidence as to what is the best way of treating men with newly diagnosed advanced prostate cancer.

Since opening in 2005 over 10 000 participants have joined the trial. We have already reported practice-changing results that show adding docetaxel or abiraterone improve disease control and life-expectancy. Several other strategies have been tested with more results expected soon, including the results of abiraterone and enzalutamide combination and radiotherapy to the prostate in men with newly-diagnosed metastatic disease.

The trial is currently recruiting to two research questions:

Can adding metformin to the treatment of prostate cancer in non-diabetic patients improve life expectancy?

Can hormone injections be substituted for hormone patches to avoid some of the side effects and achieve as good disease control?

New comparisons will open soon.

For more information on Prostate Cancer:

For more information on STAMPEDE:

Interesting in joining? A number of hospitals throughout the United Kingdom and Switzerland are participating in STAMPEDE. Please see the STAMPEDE map showing the location of these hospitals.

Looking for CRFs?

Get the quick link directly to the CRFs page to the right for fastest access..

STAMPEDE

Systemic Therapy in Advancing or Metastatic Prostate cancer: Evaluation of Drug Efficacy

See the latest News in STAMPEDE through the link to the right.